Abstract
Objective To describe the HPV-Automated Visual Evaluation (PAVE) Study, an international, multi-centric study designed to evaluate a novel cervical screen-triage-treat strategy for resource-limited settings as part of a global strategy to reduce cervical cancer burden. The PAVE strategy involves: 1) screening with self-sampled HPV testing; 2) triage of HPV-positive participants with a combination of extended genotyping and visual evaluation of the cervix assisted by deep-learning-based automated visual evaluation (AVE); and 3) treatment with thermal ablation or excision (Large Loop Excision of the Transformation Zone). The PAVE study has two phases: efficacy (2023-2024) and effectiveness (planned to begin in 2024-2025). The efficacy phase aims to refine and validate the screen-triage portion of the protocol. The effectiveness phase will examine implementation of the PAVE strategy into clinical practice, cost-effectiveness, and health communication.
Study design Phase 1 Efficacy: Nonpregnant women, aged 25-49 years, without prior hysterectomy, are being screened at nine study sites in resource-limited settings. Eligible and consenting participants perform self-collection of vaginal specimens for HPV testing using a FLOQSwab (Copan). Swabs are transported dry and undergo testing for HPV using a newly-redesigned isothermal DNA amplification HPV test (ScreenFire), which has been designed to provide HPV genotyping by hierarchical risk groups: HPV16, else HPV18/45, else HPV31/33/35/52/58, else HPV39/51/56/59/68. HPV-negative individuals are considered negative for precancer/cancer and do not undergo further testing. HPV-positive individuals undergo pelvic examination with collection of cervical images and targeted biopsies of all acetowhite areas or endocervical sampling in the absence of visible lesions. Cervical images are used to refine a deep learning AVE algorithm that classifies images as normal, indeterminate, or precancer+. AVE classifications are validated against the histologic endpoint of high-grade precancer determined by biopsy. The combination of HPV genotype and AVE classification is used to generate a risk score that corresponds to the risk of precancer (lower, medium, high, highest). During the efficacy phase, clinicians and patients will receive HPV testing results but not AVE results or risk scores. Treatment during the efficacy phase will be performed per local standard of care: positive Visual Inspection with Acetic Acid impression, high-grade colposcopic impression or CIN2+ on colposcopic biopsy, HPV positivity, or HPV 16,18/45 positivity. The sensitivity of the PAVE strategy for detection of precancer will be compared to current SOC at a given level of specificity.
Phase 2 Effectiveness: The AVE software will be downloaded to the new dedicated image analysis and thermal ablation devices (Liger Iris) into which the HPV genotype information can be entered to provide risk HPV-AVE risk scores for precancer to clinicians in real time. The effectiveness phase will examine clinician use of the PAVE strategy in practice, including feasibility and acceptability for clinicians and patients, cost-effectiveness, and health communication.
Conclusion The goal of the PAVE study is to validate a screen-triage-treat protocol using novel biomarkers to provide an accurate, feasible, cost-effective strategy for cervical cancer prevention in resource-limited settings.
Brazil Ana Ribeiro - ana-ribeiro.dantas{at}fiocruz.br
Tainá Raiol - taina.raiol{at}fiocruz.br
Center for Women’s Integrated Health, Oswaldo Cruz Foundation (Fiocruz), Brasília, DF, Brazil.
MARCO Clinical and Molecular Research Center, University Hospital of Brasília/EBSERH, Federal District, Brazil
Cambodia Te Vantha, MD, Director of Takeo Provincial Hospital,Cambodia
Thay Sovannara, MD, Medical Practitioner, Raffles Medical Group, Cambodia
Judith Norman, MD, Director of Women’s Health, Mercy Medical Center, Cambodia judynorman{at}gmail.com
Dr. Andrew T. Goldstein, Director, Gynecologic Cancers Research Foundation. drg.cvvd{at}gmail.com
Dominican Republic Margaret M. Madeleine, MPH, PhD
Program in Epidemiology, Fred Hutchinson Cancer Center
mmadelei{at}fredhutch.org
Yeycy Donastorg, MD
Instituto Dermatológico y Cirugía de la Piel “Dr. Huberto Bogaert Díaz”, HIV Vaccine Trials Research Unit, Santo Domingo, Dominican Republic. ydonastorg{at}gmail.com
El Salvador Miriam Cremer MD; Basic Health International, Pittsburgh, PA 15205, USA. Ob/Gyn and Women’s Health Institute, Cleveland Clinic, Cleveland, OH 44195, USA. miriam.cremer{at}gmail.com
Karla Alfaro, MD Basic Health International, El Salvador, kalfaro{at}basichealth.org
Honduras Miriam Cremer MD; Basic Health International, Pittsburgh, PA 15205, USA. Ob/Gyn and Women’s Health Institute, Cleveland Clinic, Cleveland, OH 44195, USA. miriam.cremer{at}gmail.com
Karla Alfaro, MD Basic Health International, El Salvador, kalfaro{at}basichealth.org.
Jaqueline Figueroa, MD, Programa Nacional contra el Cáncer, Tegucigalpa, Honduras. jacqueline_figueroan{at}yahoo.com
Eswatini Eyrun F. Kjetland, MD, PhD, Professor, Departments of Global Health and Infectious Diseases Ullevaal, Centre for imported and Tropical Diseases, Oslo University Hospital Ullevaal, Oslo, Norway; College of Health Sciences, Discipline of Public Health, Nelson Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa;Centre for Bilharzia and Tropical Health Research (non-profit), BRIGHT Academy, Durban, South Africa e.f.kjetland{at}medisin.uio.no
Teresa Norris, Founder and President, HPV Global Action, tnorris{at}hpvglobalaction.org
Zeev Rosberger, PhD, Department of Oncology, Psychology and Psychiatry, McGill University, Montreal, Canada, zeev.rosberger{at}mcgill.ca
Amelie McFadyen, MA, Chief Executive Officer, HPV Global Action, ameliemcfadyen{at}hpvglobalaction.org
Marc Steben, MD, Ecole de Sante Publique, Université de Montréal; International society for STD research, marc{at}marcsteben.com
Malawi Amna Haider, MD, Epidemiologist, Department of Epidemiology and Training, Epicentre, Dubai, UAE, amna.haider{at}epicentre.msf.org
George Kassim Chilinda, MD, Médecins Sans Frontières, Operational Centre Paris, Blantyre, Malawi, gchilinda{at}gmail.com
Henry B.K.Phiri, MD-Sexual and reproductive health department, Ministry of Health, Malawi, henryphiri06{at}gmail.com
Nigeria Ajenifuja Kayode Olusegun, MD, Obafemi Awolowo University Teaching Hospital, Ile-Ife, Osun state Nigeria, ajenifujako{at}yahoo.com
Adepiti Clement Akinfolarin, MD, Obafemi Awolowo University Teaching Hospital, Ile-Ife, Osun state Nigeria, akinfolarindepiti{at}yahoo.co.uk
Adekunbiola Banjo, MD, College of Medicine University of Lagos, Lagos, aafbanjo{at}cmul.edu.ng
Moharson-Bello Imran, MD, College of Medicine, University of Ibadan, Oyo state, Nigeria, imranmorhasonbello{at}gmail.com
Oyinloye Temitope,MD, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun state, Nigeria, projectcoordinator.itoju{at}gmail.com
Bola-Oyebamiji Sekinat, MD, College of Medicine, Osun state University, Osogbo, Osun state.
Adeyemo Marydiya, MD, College of Medicine, Osun state University, Osogbo, Osun state
Tanzania Karen Yeates-MD, MPH, Department of Medicine, Queen’s University, Kingston, Ontario, Canada, yeatesk{at}queensu.ca
Safina Yuma, MD, Cervical Cancer Focal Person, Ministry of Health, Tanzania, sychande{at}yahoo.com
Bariki Mchome, MD, Head, Reproductive Health Centre, Kilimanjaro Christian Medical Centre, Kilimanjaro, Tanzania, barikimchome{at}gmail.com
Alex Mremi, MD, Head, Department of Pathology, Kilimanjaro Christian Medical Centre, Kilimanjaro, Tanzania, alexmremi{at}gmail.com
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Cancer Institute Cancer Cures Moonshot Initiative. No commercial support was obtained. Brian Befano was supported by NCI/ NIH under Grant T32CA09168.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the National Cancer Institute has waived ethical approval for this work because it is a Consortium. All participant countries have provided their ethical approval for field studies.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Two figures have been modified for readability
Data Availability
All data produced in the present study are available upon reasonable request to the authors
